Takeda Pharmaceutical released topline data from its Phase 3 studies, SKYLINE and SKYWAY, on Soticlestat for refractory Dravet and Lennox-Gastaut syndromes
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024Promoted former VP of Finance, Mark Kowieski to Chief Financial OfficerSOLANA BEACH, Calif., June 17, 2024
Rennova Health, Inc. (OTC:RNVA) is pleased to announce that it has entered into two stock exchange agreements with FOXO Technologies, Inc., an NYSE American-listed company ("FOXO")(NYSE:FOXO). In the first agreement,
– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to work with champions at 15 healthcare sites to implement initiative activities and
New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of Observation in Children with AchondroplasiaPhase 2 and 3 Data on VOXZOGO Demonstrate Safety,
Aaron's Company shares soared as it announced an acquisition by fintech firm IQVentures for $10.10 per share, a 34% premium over its recent closing price, marking a significant shift to private ownership with a valuation around $504 million.